Genital Warts caused by HPV – treatment, recurrence, research 2018

What should you know about genital warts caused by HPV?

Anogenital warts typically develop approximately 2–3 months after HPV infection (almost all caused by types 6 or 11); however, not all persons infected with HPV types 6 and 11 develop genital warts. Anogenital warts should be assessed by a clinician and can be treated, although many warts (20–30%) regress spontaneously. Recurrence of anogenital warts within 3 months is common (approximately 30%), whether clearance occurs spontaneously or following treatment.

Read the whole manual about HPV and genital warts:

What is the most effective treatment against genital warts?

The most effective treatment (with the lowest recurrences) is called Photodynamic Therapy. Unfortunately this treatment is not available in the Western world. I mean: it is possible to get Photodynamic Therapy against i.e. ACNE on face, but it’s not possible to get it against genital warts. Why? I have no idea. Maybe it is a some kind of conspiracy? Anyway the fact is one: HPV virus hides in the skin, and it is possible to eradicate it during a few ALA-PDT treatments.

There were many clinical trials about Photodynamic therapy, but usually in China. You can check this PDF file:

What is the biggest problem with genital warts?

The biggest problem with genital warts is that they can come back, especially in the first months after their show up. All available methods (Cryotherapy, Podophyllotoxin, Aldara, Veregen…) have high recurrence rates.

What can you do to lower genital warts recurrence rate?

You can take medicinal mushrooms to boost your immune system (for example:  Coriolus versicolor and Reishi had 88% clearance rate after 2 months, during one clinical trial).

You can try food supplements like Ellagic Acid and Annona Muricata extract.  In one clinical trial EA+AM gave 74% HPV clearance rate after 6 months.

You can try use Panavir gel topically. Panavir is an antiviral medicine created in Russia. It works antiviral and immunostimulating. There are many russian clinical trials about its effectiveness.

You can try hypethermia (44-45 celsius degree) on your genitals, but it might be hard to get this treatment in any clinic.

You can combine removing warts with taking Inosine Pranobex (3g daily for 4 weeks).

If you have strong recurrences – you should check your glucose level in blood. If you have diabetes, then you should know that there is correlation between the strength of HPV/number of recurrences and diabetes.

So what can you do?

Option A:

You can go to China and try to get Photodynamic Therapy (ALA-PDT) against genital warts. That’s the most expensive option.

Option B:

You can try Cryotherapy or Podophyllotoxin, and be mentally prepared for recurrences.

Option C:

You can try Cryotherapy or Podophyllotoxin, and 1 immune-booster (i.e. medicinal mushrooms, Ellagic acid + Annona Muricata extract)

Option D:

You can try Cryotherapy or Podophyllotoxin, 1 immune-booster and – topically – Panavir gel. Panavir gel should be applied 2 times daily (5 days before the treatment, 10 days after the treatment).


Option E:

Combine Cryotherapy or Podophyllotoxin with Inosine Pranobex: 3g daily (1g in the morning/afternoon/evening) for 4 weeks. If you do this, then the chances for recurences are as low as 6-7%.

What about ALDARA?

If you are a man, then it’s a total waste of time.
If you are a woman, then you can try it (it has 60% effectiveness in females).

What about ACV, Thuja, homeopathic medicines?

Forget about it. It’s your health. Don’t waste your time on methods without any clinical trials. You can check Google Scholar and search for clinical trials.

Panavir from Russia – alternative treatment for HPV and genital warts

Panavir – biologically active substance of Panavir is ”GG17” – plant polysaccharide, relating tohexose glycoside class. It main dosage form – intravenous solution 0,004% in 5 ml ampoules (single therapeutic dose). Additional dosage form: rectal suppositories, vaginal suppositories, gel for outward application. Preparation has original pharmacologic property, non-toxic in therapeutic dose (LD50 ~ 3000 therapeutic dose). It is successfully used where ordinary antiviral preparations are not effective or contraindicative or have unsatisfactorily effect: chronic tick-borne encephalitis, ophthalmoherpes, herpes zoster (shingles), cytomegalovirus, Epstein-Barr virus, Human papilloma virus. Now Panavir tests for treatment chronic hepatitis B and C.

Biologically active substance of Panavir is ”GG17” – plant polysaccharide from Solanum tuberosum. GG17 is a high-molecular hexose glycoside with complex structure: Glucose (38,5%), Galactose (14,5%), Rhamnose (9%), Mannose (2,5%), Xylose (1,5%), Uronic acid (3,5%).

Preparation was developed by the company National Research Company jointly with Research Institute of Physicochemical Medicine, Ministry of Health and Social Development of the Russian Federation, under the direction of the academician of RAMS Sergienko V.I.


This research is devoted to determination of the clinical efficacy of Panavir in the combined therapy of the uterine cervix diseases associated with human papillomavirus (HPV). The article presents data of the complex examination of 59 patients. Patients with diagnosed 16th, 18th, 31st, 33rd types of HPV underwent destructive methods of treatment of the cervix followed by Panavir. The efficacy of Panavir was estimated by PCR in 3, 6 and 12 months from the beginning of treatment and it was 84,7%. Antiviral therapy permits to prevent recurrence of papillomavirus infection of the cervix uteri.


All the patients were given Panavir rectal suppositories in a daily dose of 200 mg for 10 days. Radio waves were used to destroy anogenital warts in Group 1 patients. The patients were examined using laboratory monitoring immediately and 30, 60, and 90 days after therapy. Results. Following 3 months of Panavir therapy in combination with radio wave mass destruction, human papillomavirus DNA was not detected in 80% of the patients; remission was recorded in 90%. After 3 months of Panavir use, 85% of the patients with latent infection were found to cease human papillomavirus DNA excretion. Conclusion. The high clinical efficacy of Panavir suppositories permits one to recommend the agent in this formulation for wide practical application.



The article presents the results of treatment of 51 men with recurrent genital HPV infection in the form of genital warts. Patients were divided into two groups depending on the treatment. Group 1 of patients has received the combination treatment–electrocoagulation + pharmacotherapy (panavir intravenously and topically in the form of a gel), Group 2 of patients–only electrocoagulation. According to the results of follow-up within 6 months, disease recurrence rate was significantly higher in Group 2–39.5% versus 9.6% in the Group 1. Postoperative complications were also more frequently recorded in the Group 2. These findings suggest that the combined treatment of reccurent forms of genital warts is preferred than just using destructive methods of treatment.


The efficiency of combined therapy in patients with HPV-associated chronic endocervitis was investigated. The antiviral preparation modulating immune response (panavir) was used. The results showed that panavir increases the efficiency of therapy and eliminates the HPV in 96,6% of patients.



The results of combination therapy were comparatively analyzed in 60 patients with human papillomavirus (HPV)-associated cervical neoplasias. Thirty patients in the study group were given the antiviral and immunomodulatory drug – intravenous and intravaginal panavir before destructive treatment. Thirty patients in the control group had traditional destructive treatment. It has been ascertained that the use of systemic and local combination antiviral therapy before destructive treatments enhances the efficiency of the therapy performed, promotes a reduction in process relapsing, and leads to HPV elimination in 85% of cases.


I found informations about Panavir when I was searching for clinical trials about HPV and genital warts. I have learned that Panavir is very effective in combined therapy. It lowers recurrences of genital warts and increase the speed of HPV clearance.

I think that the best approach is combined therapy: Cryotherapy (or Podophyllotoxin) to remove genital warts, and Panavir gel to avoid recurrences.


HPV treatment – HPV cure research 2018

Prologue: How to deal with HPV?

A) Don’t PANIC!
B) Learn about HPV from reliable sources, for example:
C) Don’t waste your money on food supplements without any clinical trials (like Echinacea, Astralagus, Zinc…)

There is no cure for HPV but you can still fight with the virus.

How to get rid of HPV faster?

1) Quit smoking
2) Quit drinking
3) Check glucose level in your blood – there is a correlation between HPV strength/recurrence of genital warts (if you have HPV6/11) and diabetes.
4) Eat healthy food, eat lots of vegetables
5) Lower your sugar/carbohydrates intake. Cancer and HPV love sugar.
6) Exercise 2-3 times per week
7) You can try medicinal mushrooms:
– Coriolus versicolor boost immune system
– Reishi fights directly with HPV* and cancer cells*
– Chaga has strong anti-viral activity

IMPORTANT: buy only alcohol/water reishi extracts because they have active ingredients. Avoid powdered reishi – it’s not better than placebo.

– Lentinan (from shiitake mushrooms) lowers genital warts recurrence

* – In this study, we investigated the effects of the aqueous extracts of Lingzhi or Reishi medicinal mushroom, Ganoderma lucidum, obtained from three localities (China; and Morelos and Michoacan, Mexico) on cervical cells transformed by human papillomavirus (HeLa and SiHa) and C-33A cancer cells. The cells were plated in DMEM medium supplemented, and were incubated in the presence of different concentrations of G. lucidum for 24 h. Cell proliferation was determined by MTT colorimetric assay and viability by trypan blue assay. Inhibitory dose was determined (IC50) of the three different extracts of G. lucidum in the culture cell lines mentioned above. The apoptosis process was confirmed by nuclear DNA fragmentation and the cell cycle was determined by flow cytometry. The results showed that aqueous extracts G. lucidum obtained from three localities produced inhibition in the proliferation of VPH transformed cells; they also induced apoptosis and cell cycle arrest in HeLa, SiHa, and C-33A cancer cells. Therefore, it was found that aqueous extracts G. lucidum obtained from three different locations produced inhibitory effect on cancer cells and may have a potential therapeutic use for the prevention and treatment of this disease.

8) Vaccine yourself against HPV – it will not help your current infection, but it can protect you against other HPV strains. The best vaccine is called “Gardasil” and “Gardasil 9”.

How to get rid of genital warts?

You can try:
– Podophyllotoxin (it’s very effective, very fast, but you can get skin infection)
– Imiquimod/Aldara (it’s an immunomodulator, you will wait longer to see the effects; Imiquimod is much less effective in case of men)
– Veregen (it’s a green tea extract, it’s effective but very expensive; you will wait very long to see the effects)
– Panavir (antiviral medicine made in Russia; it’s available i.e. as a gel)
– combine Cryotherapy or Podophyllotoxin with Inosine Pranobex (antiviral medicine)

You can ask your doctor for:
– electrocauterization (it’s painful)
– laser treatment
– cryotherapy (the fastest and the cheapest option)
– photodynamic therapy (the best option but it’s hard to get photodynamic therapy against genital warts; many dermatologists don’t know that photodynamic therapy can be used against genital warts)

In general the best options for HPV are:
– check your glucose level and avoid junk food/sugar
– take medicinal mushrooms – Coriolus versicolor 3g/daily in the morning, Reishi (Lingzhi) 1-2g/daily in the evening.,266d4152107fca7a,3512deba5cc9e72b.html
– take Ellagic acid and Annona Muricata extract (check details below)

In general the best options for HPV genital warts are as above, and additionally:
– use Podophyllotoxin for small warts
– use Cryotherapy for big warts
– try to get Photodynamic Therapy
– try Panavir, it’s very effective in combined therapy, when i.e. Cryotherapy removes the warts, and Panavir lowers the chances of recurrences
– combine Cryotherapy or Podophyllotoxin with Inosine Pranobex


2018 UPDATE:

Hyperthermia vs. HPV and genital warts

In the current report, the investigators demonstrate that APOBEC3A and APOBEC3G expression levels are increased in genital warts (condyloma acuminata) compared with normal tissues, in which APOBEC3G is barely detectable (Yang et al., 2017). On heat treatment to 42 °C and 45 °C, there is a significant increase in APOBEC3A and APOBEC3G mRNA transcripts in condyloma acuminate, up to 10-fold. Again, this effect is not observed in normal skin.

Although hyperthermia is not as widely used as cryotherapy in treating warts, including genital warts, it is interesting to note that hyperthermia seems to have an advantage as it is not destructive, but, rather, appears to stimulate antiviral and immunological pathways that are reminiscent of the use of imiquimod. This study provides an elegant explanation for the observed clinical effects of hyperthermia on warts. What is unclear is whether APOBEC3A and APOBEC3G expression contribute not only to editing HPV and limiting its replication, but also whether these mutations increase immune responses against the virus. Hyperthermia, in contrast to cryotherapy, would be an elegant way to expose the virus in a meaningful way to immune reactivity and even prevent recurrences, an effect similar to that of imiquimod when used to treat genital warts.

Ellagic acid and Annona Muricata vs. HPV and L-SIL

Ellagic acid (EA) and Annona Muricata (AM) have antioxidant, anticarcinogenic and antiviral activity demonstrated by in vitro models. This pilot study investigated the in vivo potential anti-viral activity in women affected by Low squamous intraepithelial lesion (L-SIL) related to high risk human papilloma virus (HR-HPV), and the ability to modify the oncoproteins expression in the cervical lesion thickness. Sixty women affected by HR-HPV related L-SIL, were randomly divided into two groups: group A (n = 30) supplemented with EA (16 mg) + AM (100 mg) 2 times daily for 6 months and group B (n = 30) administered with placebo. HR-HPV clearance was obtained in 74% of cases in group A compared to 25% of cases in group B (p = 0.001) and p21 expression in LSIL thickness increased in 63.2% of cases in group A compared to 20% in group B (p = 0.03). AE/AM supplementation significantly induces HR-HPV elimination and stimulates p21 expression in LSIL thickness.

2018 UPDATE 2:

Check clinical trials about Panavir, antiviral medicine made in Russia:


2018 UPDATE 3:

Combine Cryotherapy or Podophyllotoxin (to remove warts) with Inosine Pranobex (to lower recurrences):

This study evaluates the effectiveness of immunomodulating drug isoprinosine in a comprehensive treatment of genital warts in men. Most of the patients were aged 20-30 years. The combination therapy was found to have long term effectiveness. In the group of patients undergoing only destructive methods of treatment relapse after 8 month follow-up was diagnosed in 32% and in patients of the combination therapy group (destruction plus isoprinosine) – in 7% of patients. The pharmacological action of the drug (immunostimulating, antiviral) and the effectiveness of its combination with destructive therapies justify the use of inosine pranobex (isoprinosine) both in the complex therapy of genital warts and for the prevention of the disease recurrence.


Lentinan from shiitake mushrooms vs. HPV

Objective: To observe the immunomodulatory and therapeutic effect of lentinan in treating condyloma acuminatum (CA).Methods: Thirty-six CA patients were randomly divided into two groups, 19 in the treated group treated with lentinan and CO2 laser irradiation, and 17 in the control group, treated with laser irradiation alone. Their T lymphocyte subsets of peripheral blood and level of serum interleukin-2 (IL-2) and soluble interleukin-2 receptor (SIL-2R) were determined before and after treatment, and the recurrence rates of the two groups were compared.Results: After treatment, in the treated group, the CD4/CD8 ratio, serum IL-2 raised and serum SIL-2R lowered significantly (P < 0.05, 0.05, 0.05 respectively) as compared with before treatment, while those parameters were not changed significantly in the control group. The recurrence rate of the treated group was lower than that of the control group.P < 0.05.Conclusion: Lentinan could modulate the cellular immunofunction of CA patients and reduce the recurrence rate of CA cases.

Comparison of Recurrence Rate of Two Groups after Treatment:

Ten among 36 cases showed recurrence, the recurrence rate was 27.78%; among them, 2 of the treated group were recurrent, the recurrence rate was 10.53%; while that of the control group [the recurrence rate] was 47.06% (8/17 cases). The difference of the recurrence rate of two groups was significiant.

Check the whole clinical trial: Immunomodulatory and therapeutic effect of lentinan in treating condyloma acuminatum

How to cure HPV genital warts with Photodynamic therapy

Photodynamic therapy (ALA-PDT) is usually used against ACNE, but it’s off label usage (against genital warts) is very effective and has very low reccurence rate.

Study 1:

The patient, a 30-year-old man with numerous genital condylomata acuminata (CA), has had unsuccessful treatment with liquid nitrogen, 20% podophyllin, and repeated 0.5% podophyllotoxin solution with 5% imiquimod (Figure 1). Before the appearance of CA, he experienced acute orchiepididimitis and a Candida infection. The patient was immunologically examined, and the lower level of lymphocytes, slightly reduced level of IgM, and C4 complement were revealed. Results from a human immunodeficiency virus examination were negative. After the therapeutic failure mentioned above, photodynamic therapy (PDT) was initiated using 20% aminolevulinic acid (5-ALA) in a gel. The photosensitizer was applied to lesions and 10 mm of surrounding skin in a 1-mm-thick layer under occlusive dressing for 3 hours and then removed with saline and nonwoven gauze. The site was immediately irradiated with noncoherent red light with an emission spectrum of 580 to 680 nm wavelength (Medeikonos PDT-Model 200, Medeikonos AB, Sweden). The total light dose was 50 J/cm(2); light intensity ranged from 70 to 90 mW/cm(2). Because of persistent fluorescence during photodynamic therapy, the treatment was repeated 10 times in 2-week intervals with a follow-up of 1, 3, and 6 months after its completion. After the last PDT treatment, the persistent fluorescence disappeared completely. The absence of fluorescence corresponded with a healed clinical finding without scarring and pigmentation (Figure 2). The period from the initiation of PDT to the consolidation of CA was 22 weeks. During PDT treatment, the patient felt only mild burning, which disappeared after the illumination stopped. Six months after the therapy, there were no signs of recurrent disease.

Source: Genital warts treated by photodynamic therapy.

Study 2:

Our trial provided a complete cure rate of nine of 15 subjects after five PDT sessions. Perianal lesions showed a particularly rapid remission. While progressing towards total lesion clearance, the immunohistochemical pattern was dominated by dense CD4+ T lymphocytes infiltrating the superficial dermis, accompanied by an accumulation of Langerhans cells. Simultaneously, CD8 began to increase in the lesions of responding patients, and Langerhans cells seemed to migrate towards the dermis. CD68+ macrophages apparently did not participate in the immune inflammatory response.

Source: Immunological activity of photodynamic therapy for genital warts.

Study 3:

Genital warts were relieved in 107 out of the 110 cases (cure rate: 97.3%). Male patients had significantly better treatment outcomes at the urethral orifice than those in other affected parts. In the 107 patients, the cure rate of male patients was 98.8%, and they were cured after being treated four times. In contrast, female patients, who were cured after 5 times of treatment, had the cure rate of 91.7%. Their cure rates were similar (χ(2)=0, P>0.05), but the males were cured after significantly fewer times of treatment than the females (t=-7.432, P<0.05). Five patients suffered from mild tingling or burning sensation upon dressing at the urethral orifice, and the others were all free from systemic adverse reactions. After illumination, a small portion of the patients had mildly red, swelling, painful affected parts, with mild edema that almost disappeared within three days. Three patients relapsed at the urethral orifice and were then cured after further treatment.

Source: Therapeutic effects of topical 5-aminolevulinic acid photodynamic therapy.

European Dermatology Forum about Photodynamic therapy:

Download PDF file and look at point 6.6

Check other clinical studies about Photodynamic therapy vs. genital warts:

Download PDF file